• Halozyme Therapeutics Inc., of San Diego, Calif., began a Phase Ib/II trial of PEGPH20 in combination with FOLFIRINOX chemotherapy compared to FOLFIRINOX alone in metastatic pancreatic adenocarcinoma. The trial will enroll about 144 patients. The initial Phase Ib portion of the trial will confirm the optimal dose of PEGPH20 for the Phase II potion, which will evaluate overall survival. Secondary endpoints include progression-free survival, objective tumor response, and adverse events.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter